
ProQR Therapeutics (PRQR) Stock Forecast & Price Target
ProQR Therapeutics (PRQR) Analyst Ratings
Bulls say
ProQR Therapeutics NV is positioned favorably due to its focus on advancing RNA therapeutics for severe genetic rare diseases, with a pipeline that shows potential for expedited clinical advancement and proof of concept achievements. The Axiomer RNA base-editing platform is considered promising, with expectations for upcoming clinical data to enhance the company’s valuation. Successful execution in advancing its pipeline could significantly lead to stock price appreciation, indicating a robust outlook for investors.
Bears say
ProQR Therapeutics NV faces a negative outlook primarily due to the inherent risks associated with its Phase Ib/II/III clinical studies, which could significantly affect share performance based on their outcomes. Additionally, the company may encounter limited early revenue potential for its product AX-0810, given the smaller patient population it targets compared to its competitors, which could hinder growth prospects. Furthermore, the evolving landscape of treatment methods for genetic rare diseases poses a substantial threat, as successful new therapies may render ProQR's existing products non-competitive or obsolete.
This aggregate rating is based on analysts' research of ProQR Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
ProQR Therapeutics (PRQR) Analyst Forecast & Price Prediction
Start investing in ProQR Therapeutics (PRQR)
Order type
Buy in
Order amount
Est. shares
0 shares